EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Heterogeneity of Treatment Effects Across Nine Glucose‐Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND ‐ T2DM Network Study

Hsin Yi Chen iD, Thomas Falconer, Anna Ostropolets, Tara V Anand, Xinzhuo Jiang, David Dávila-García iD, Linying Zhang, Ruochong Fan, Hannah Morgan-Cooper, Marc A Suchard, George Hripcsak

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70918 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Hsin Yi Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NLM NIH HHS, Advanced Research Projects Agency for Health, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Understanding heterogeneous responses to glucose‐lowering therapies is crucial for advancing personalized treatment and optimizing outcomes in type 2 diabetes mellitus (T2DM). While average treatment effects are established for many drug classes, responses may vary by clinical and demographic factors. Here, we evaluated whether major glucose‐lowering drug classes exhibit heterogeneous treatment effects (HTE) across key patient characteristics. Materials and Methods This large‐scale observational cohort study was replicated in six data‐sources across the Observational Health Data Sciences and Informatics network. New‐user, active‐comparator cohorts were constructed for patients with T2DM initiating one of the nine antihyperglycemic drug classes. Large‐scale propensity score adjustment, empirical calibration using negative controls, and random‐effects meta‐analysis were used to estimate calibrated hazard ratios (HRs). HTE was assessed by comparing differences in log HRs across clinical and demographic subgroups.

Results

Nominal signals of HTE were observed in the hyperlipidemia, hypertension, obesity, and sex subgroups: Biguanides (vs. DPP‐4 inhibitors) were associated with lower risk of acute myocardial infarction in hyperlipidemia and heart failure hospitalization in obesity. SGLT‐2 inhibitors (vs. GLP‐1 receptor agonists) were associated with reduced stroke risk only in non‐obese patients. Sex‐specific patterns included higher risk of diarrhoea with GLP‐1 receptor agonists and lower risk of stroke with SGLT‐2 inhibitors (both vs. DPP‐4 inhibitors) in women. None of the signals demonstrated statistical significance after multiple testing correction. Several subgroups (e.g., diabetic ketoacidosis and retinopathy) did not meet diagnostic criteria for clinical reliability and were not evaluated.

Conclusions

This hypothesis‐generating study identified limited signals of HTE. These findings are exploratory and require cautious interpretation and validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsHumansFemaleMaleTreatment Effect HeterogeneityMiddle AgedAgedDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsInsulin SecretagoguesBiguanidesSulfonylurea CompoundsCohort StudiesThiazolidinedionesGlucagon-Like Peptide-1 Receptor AgonistsTreatment OutcomeBlood Glucose

Stichwörter der Autor:innen

comparative effectivenessglucose‐lowering drugsheterogeneity of treatment effectobservational studypersonalized medicinereal‐world evidence

Substanzen

Hypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsInsulin SecretagoguesBiguanidesSulfonylurea CompoundsThiazolidinedionesGlucagon-Like Peptide-1 Receptor AgonistsBlood Glucose

Autor:innen und Institutionen

  • Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
  • Johnson & Johnson, Titusville, New Jersey, USA.
  • Institute for Informatics, Data Science and Biostatistics, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Stanford School of Medicine and Stanford Health Care, Palo Alto, California, USA.
  • Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, USA.
  • VA Informatics and Computing Infrastructure, United States Department of Veterans Affairs, Salt Lake City, Utah, USA.

ORCID-Profile: Hsin Yi Chen, David Dávila-García

Förderung

  • NLM NIH HHS
  • Advanced Research Projects Agency for Health
  • NHLBI NIH HHS
  • U.S. National Library of Medicine
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Chen, H. Y., Falconer, T., Ostropolets, A., Anand, T. V., Jiang, X., Dávila-García, D., Zhang, L., Fan, R., Morgan-Cooper, H., Suchard, M. A., & Hripcsak, G. (2026). Heterogeneity of Treatment Effects Across Nine Glucose‐Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND ‐ T2DM Network Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70918

Vancouver

Chen HY, Falconer T, Ostropolets A, Anand TV, Jiang X, Dávila-García D, et al. Heterogeneity of Treatment Effects Across Nine Glucose‐Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND ‐ T2DM Network Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70918

BibTeX
@article{Chen2026,
  author = {Chen, Hsin Yi and Falconer, Thomas and Ostropolets, Anna and Anand, Tara V and Jiang, Xinzhuo and Dávila-García, David and Zhang, Linying and Fan, Ruochong and Morgan-Cooper, Hannah and Suchard, Marc A and Hripcsak, George},
  title = {Heterogeneity of Treatment Effects Across Nine Glucose‐Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND ‐ T2DM Network Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70918}
}
Kostenlos starten →